Assessment of a New Fluorescence Imaging Technique Using Biopsies From Prostate Resection

NCT03157856•University Hospital, Grenoble

Summary

In this study, we aim to evaluate the feasibility of anti-PSMA labelling to detect post-operative prostatic tissues by two ex vivo fluorescence techniques. We will evaluate the feasibility and detection of anti-PSMA labelling by: 1. / the FEMTO-ST institute medical device, 2. / the confocal microscope that will be used to measure fluorescence spectra of biological samples.

Detailed Description

For this protocol, 12 patients will be included.

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•male patient over 18 years old
•patient with indication for radical prostatectomy
•patient with a rectal palpable nodule or targeted MRI positive biopsies or with at least 4 positive biopsies in a hemi-prostate.
•* patient affiliated to French social security system or equivalent
•* patient who have signed a non-opposition form

Exclusion Criteria

•patient with contraindication to radical prostatectomy
•patient with remedial prostatectomy
•patient with normal preoperative MRI or with absence of tumoral area
•patient with history of hormonal therapy
•person deprived of freedom by judicial or administrative decision
•person under legal protection
•person hospitalized for psychiatric care.

Locations (2)

Grenoble Alpes University Hospital - Urology department

Grenoble, France

Grenoble Alpes University Hospital

Grenoble, France

Key Dates

Start Date

May 11, 2017

Primary Completion Date

October 7, 2018

Completion Date

January 8, 2019

Last Updated

January 15, 2019

Enrollment

ACTUAL participants

Conditions

Cancer Prostate

Interventions

Fluorescence assessment

OTHER

Prospective Validation of PSMA-RADS

NCT06359717

Cancer Prostate

View study

COMPLETEDPHASE4

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study

NCT04074460

Cancer, BreastCancer Colorectal+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 15, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions